SCHEMBL1198550

SCHEMBL1198550

O=C(c1ccsc1)c1cc(I)ccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
DAO P14920 1/20 0.42
HDAC1 Q13547 1/20 0.39
ANO1 Q5XXA6 1/20 0.37
MDM2 Q00987 1/20 0.36
HSD17B14 Q9BPX1 1/20 0.34
C5AR1 P21730 1/20 0.34
PTPN1 P18031 1/20 0.34
MAPK14 Q16539 1/20 0.34
HPGD P15428 1/20 0.34
MAP2K2 P36507 2/20 0.34
MAP2K1 Q02750 2/20 0.34
ADORA2A P29274 1/20 0.34
ADORA1 P30542 1/20 0.34
KCNK3 O14649 1/20 0.33
KCNK9 Q9NPC2 1/20 0.33
ERN1 O75460 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100175 0.77 CES2 (0.48) CES2CES1LCKFYNDAO
SCHEMBL1198646 0.76 NR4A1 (0.46) CES2CES1ANO1MDM2MAP2K1
SCHEMBL31612030 0.74 CES2 (0.54) CES2CES1LCKFYNDAO
SCHEMBL1309846 0.72 TUBB4A (0.50)
SCHEMBL2166098 0.71 CES2 (0.71) CES2CES1LCKFYNDAO
SCHEMBL1199143 0.71 MAP2K1 (0.47) HSD17B14MAPK14MAP2K1
SCHEMBL15318295 0.70 CES2 (0.48) CES2CES1LCKFYNDAO
SCHEMBL78403 0.70 MAP2K1 (0.53) CES2CES1ANO1PTPN1MAP2K2
SCHEMBL17112809 0.70 CES2 (0.44) CES2CES1LCKFYNDAO
SCHEMBL8067455 0.69 GABRA1 (0.51) HDAC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812112-B1 Benzodiazepine derivatives as ROCK kinases inhibitors GLAXOSMITHKLINE LLC (US) 2011-04-27 EP disclosed
EP-1812112-B1 Benzodiazepine derivatives as ROCK kinases inhibitors GLAXOSMITHKLINE LLC (US) 2011-04-27 EP disclosed
US-7888503-B2 Benzodiazepine derivatives that inhibit rock GLAXOSMITHKLINE LLC (US) 2011-02-15 US disclosed
US-7888503-B2 Benzodiazepine derivatives that inhibit rock GLAXOSMITHKLINE LLC (US) 2011-02-15 US disclosed
US-20090143366-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2009-06-04 US disclosed
US-20090143366-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2009-06-04 US disclosed
EP-1812112-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2007-08-01 EP disclosed
WO-2006044753-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143366-A1 CHEMICAL COMPOUNDS ROCK2, ROCK1, ABL1 CES2 1589/4885CES1 3374/4885LCK 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.